Status:
COMPLETED
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
Lead Sponsor:
Ohio State University
Collaborating Sponsors:
Lundbeck LLC
Conditions:
Huntington's Disease
Eligibility:
All Genders
18+ years
Brief Summary
In individuals with Huntington's disease (HD), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fa...
Detailed Description
Individuals with HD who are ambulatory and are either already taking Xenazine or have been newly prescribed the medication will be recruited for this prospective open-label study. A variety of motor a...
Eligibility Criteria
Inclusion
- Huntington's Disease
- Able to ambulate independently
Exclusion
- Other orthopedic or neurological disorder that affects gait or balance
- Pregnancy
- Chorea score \<10 prior to initiation of medication.
- Inability to provide informed consent
Key Trial Info
Start Date :
April 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01451463
Start Date
April 1 2010
End Date
April 1 2013
Last Update
November 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ohio State University Medical Center
Columbus, Ohio, United States, 43210